NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements.
The National Institute for Health and Care Excellence (NICE) has published updated Interventional Procedures Guidance (IPG) supporting the use of the alfapump® for the treatment of refractory ascites caused by cirrhosis.
Ascites, a key complication of liver cirrhosis, is the accumulation of ascitic fluid in the abdomen. Patients may accumulate as much as 10 to 15 litres of ascitic fluid within the abdomen every 15 days.
“Refractory ascites has a huge effect on patient’s quality of life” commented Judi Rhys, Chief Executive of the British Liver Trust. “Those affected report feelings of isolation and depression as they cannot do their daily activities. The NICE guidance for the use of the alfapump® in patients suffering from this debilitating complication of liver disease is an important step forward for the patient community and their caregivers. We are enthused by the possible reduced hospital admissions and improved quality of life this new treatment option may offer.”
For further information, please visit: http://ouroffering.sequanamedical.com/